The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 12, 2021

Filed:

Mar. 23, 2017
Applicant:

Research Triangle Institute, Research Triangle Park, NC (US);

Inventors:

Scott Runyon, Hillsborough, NC (US);

Carla Hassler, Durham, NC (US);

Craig Shiner, Durham, NC (US);

Sanju Narayanan, Durham, NC (US);

Assignee:

Research Triangle Institute, Research Triangle Park, NC (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 5/02 (2006.01); C07K 5/065 (2006.01); A61K 31/4015 (2006.01); A61K 31/55 (2006.01); C07D 207/416 (2006.01); A61K 31/495 (2006.01); A61P 25/20 (2006.01); C07C 237/24 (2006.01); A61P 25/30 (2006.01); C07D 211/60 (2006.01); C07D 223/20 (2006.01); C07K 11/00 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
C07K 5/0202 (2013.01); A61K 31/4015 (2013.01); A61K 31/495 (2013.01); A61K 31/55 (2013.01); A61P 25/20 (2018.01); A61P 25/30 (2018.01); C07C 237/24 (2013.01); C07D 207/416 (2013.01); C07D 211/60 (2013.01); C07D 223/20 (2013.01); C07K 5/06078 (2013.01); C07K 11/00 (2013.01); A61K 38/00 (2013.01); C07C 2601/14 (2017.05); C07C 2602/42 (2017.05); C07C 2602/44 (2017.05);
Abstract

Neuropeptide S receptor agonists are provided. The NPS agonists include peptidomimetic analogs exhibiting affinity for and activity at the neuropeptide S receptor. The molecules may be useful in the treatment of disorders, syndromes and conditions mediated by modulation of the neuropeptide S receptor such as substance abuse, narcolepsy, insomnia, obesity, cognitive decline, dementia, Alzheimer's disease, panic disorder, generalized anxiety, PTSD, phobias, schizophrenia and as supportive medication during any kind of cessation program in cognitive behavioral therapy, such as drug addiction, eating disorders and gambling.


Find Patent Forward Citations

Loading…